Medicines New Zealand Unveils 2022 Transfer of Value Reports to Enhance Transparency

By Staff Writer

August 30, 2023

Medicines New Zealand is delighted to announce the launch of the 2022 Transfer of Value reports. These reports, representing the organisation’s second annual publication, offer a transparent snapshot of the financial interactions between biopharmaceutical companies and healthcare professionals. This initiative underscores our unwavering commitment to transparency and ethical standards within the industry.

Dr Graeme Jarvis, CEO of Medicines New Zealand, remarked on the release, “This information is what the joint project between industry and healthcare practitioners was designed to deliver.”

The reports aim to shed light on the financial relationships and interactions between biopharmaceutical companies and healthcare professionals. They seek to bolster transparency and uphold ethical standards within the industry.

“Public reporting of payments made by the biopharmaceutical industry to healthcare professionals is the right thing to do from a transparency perspective,” said Dr Jarvis. “This commitment allows patients and the public to gain insight into the nature of these interactions and have confidence in the ethical standards and patient-centric approach of healthcare professionals in New Zealand.”

The 2022 Transfer of Value reports provide a comprehensive overview of the financial interactions between Medicines New Zealand member companies and healthcare professionals. These interactions include sponsorships for healthcare providers to attend medical education events and conferences, which ultimately benefit patient care and contribute to the continuous improvement of healthcare practices.

Medicines New Zealand invites all interested parties to access the Transfer of Value reports from its member companies. The reports serve as a valuable resource for those seeking a deeper understanding of the financial relationships that drive advancements in patient care.

Reference url

Recent Posts

diabetes medicine access
               

Improving Diabetes Medicine Access: Key Changes in the Pharmaceutical Benefits Scheme

🚀 Are we on the verge of a breakthrough in diabetes medication accessibility?

The latest updates to the Pharmaceutical Benefits Scheme (PBS) are set to transform type 2 diabetes management by expanding access to essential medicines like empagliflozin and streamlining the prescribing process for glucagon-like peptide 1 receptor agonists (GLP-1 RAs). These changes not only prioritize equity for high-risk populations but also align with global trends in cost-effective healthcare.

Dive deeper into how these revisions could reshape diabetes care and promote better health outcomes for all.

#SyenzaNews #HealthcareInnovation #healthcare #MarketAccess

HPV testing HNSCC
    

HPV Testing in Head and Neck Squamous Cell Carcinoma

🔍 Are you up-to-date with the latest advancements in HPV testing for head and neck cancer?

Our comprehensive article looks into the innovation of diagnostic methods for HPV status determination in head and neck squamous cell carcinoma (HNSCC). From traditional p16 immunohistochemistry to innovative liquid biopsies, discover the critical role these advancements play in prognosis, treatment planning, and improving patient outcomes.

Look into this essential topic and see how these insights could revolutionize clinical practices.

#SyenzaNews #oncology #HealthTech #HealthcareInnovation

oral health Africa
    

Oral Health in Africa: Promoting Collaborative Solutions

🦷 Is oral health taking a back seat in public health discussions in Africa?

A new article reveals alarming statistics about the high prevalence of untreated dental diseases across the continent and a critical shortage of oral health professionals. It emphasizes the urgent need for collaborative action among healthcare providers and policy-makers to integrate oral health into broader public health frameworks.

Discover how strengthening partnerships can pave the way for improved health outcomes and resource allocation in oral health.

#SyenzaNews #globalhealth #HealthEconomics

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.